CROHN'S DISEASE

This study looks at whether a special liquid diet called exclusive enteral nutrition (EEN) can help adults with active Crohn's disease feel better and reduce inflammation. About 300 participants will use EEN as their main treatment for 12 weeks. Researchers will track remission r…

This study tests an experimental drug called SAR441566 in 260 adults with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms compared to a placebo. Participants will receive the drug or placebo for up to 52 weeks, with an…

This study looks at whether adding a coping skills program to standard biologic medication can improve emotional well-being and disease remission in people with early Crohn's disease. About 170 adults diagnosed within the last 5 years and starting a new biologic will be randomly …

This study looks at whether vedolizumab can help people with moderate to severe ulcerative colitis or Crohn's disease achieve remission (no symptoms) after 14 weeks of treatment. About 400 adults aged 18 to 80 will receive vedolizumab first as an IV infusion, then as a shot under…

This study is for people with Crohn's disease whose current medicine (adalimumab) is no longer working well. It compares two options: increasing the dose of adalimumab or switching to a different drug called vedolizumab. The goal is to see which approach better controls symptoms …

This program offers continued access to vedolizumab, given as an IV infusion, for children and teenagers with moderate to severe ulcerative colitis or Crohn's disease who completed a prior study and still benefit from the treatment. It is designed for those without suitable alter…

This study looks at the long-term safety of the drug vedolizumab in children with ulcerative colitis or Crohn's disease. It is for kids who already completed a previous vedolizumab study. Researchers will track side effects and major bowel-related events over time.

This study tests an experimental drug called AZD7798 in 30 adults with active Crohn's disease who have an ileostomy (a surgically created opening in the belly for waste). The goal is to see if the drug is safe and can help repair the lining of the small intestine compared to a pl…

This study follows about 240 people in Japan with moderate to severe Crohn's disease who are taking the approved drug upadacitinib. Researchers will track side effects and how well the drug controls the disease over up to 64 weeks. The goal is to see how the drug works in everyda…

This study tests a drug called mirikizumab in about 90 children with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining over 52 weeks, with a safety follow-up. Participants will receive the drug or another treatment and attend…

This study tracks 275 people in Japan who receive darvadstrocel injections for complex anal fistulas caused by Crohn's disease. Researchers will monitor side effects and check if the treatment helps close the fistulas over 36 months. The goal is to see if this cell therapy can im…

This study tests an oral medication, upadacitinib, in children aged 2 to 18 with moderate-to-severe Crohn's disease who haven't improved with standard treatments. The goal is to see if the drug can reduce inflammation and improve symptoms. Participants will take the drug daily an…

This study tests whether combining two different drugs (vedolizumab with either adalimumab or ustekinumab) can better control moderate to severe Crohn's disease. About 100 adults will receive the combination for 26 weeks, then those who respond will switch to vedolizumab alone. T…

This study tests several new investigational drugs in 140 adults with moderate-to-severe Crohn's disease or ulcerative colitis. The goal is to see if these drugs are safe and can improve symptoms and gut healing. Participants must have a confirmed diagnosis and meet disease activ…

This study tests an experimental drug called SAR442970 in adults with moderate to severe Crohn's disease. About 99 participants will receive either the drug or a placebo to see if it can reduce gut inflammation and improve symptoms. The goal is to find a better treatment option f…

This study looks at the long-term safety of a drug called vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who responded well to the drug in an earlier study will continue treatment, while others who did not respond well will…

This study watches how well IL-23 inhibitors work for adults with active Crohn's disease in everyday medical practice. About 665 participants will get treatment chosen by their doctor and be checked at 12 and 52 weeks for symptom relief, healing, and side effects. The goal is to …

This study tests whether adding the antifungal drug fluconazole to standard IL-23 therapy helps people with Crohn's disease feel better. About 120 adults with mild to moderate Crohn's will receive either fluconazole or a placebo alongside their usual treatment. The main goal is t…

This study tests an oral drug called TAK-279 in 268 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. The main goal is to see if three different doses can reduce bowel inflammation and ulcers after 12 weeks compared to a placebo. Parti…

This study tests a drug called guselkumab in 120 children with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms over 52 weeks. Participants must have active disease confirmed by endoscopy. This is a phase 3 trial, meani…

This early-phase study tests whether the drug vorinostat is safe and can help control moderate-to-severe Crohn's disease. Participants who respond well may then receive long-term maintenance therapy with another drug, ustekinumab, for up to two years. The goal is to reduce gut in…

This study looks at the long-term safety of an oral medication called zasocitinib (TAK-279) for people with moderate to severe Crohn's disease or ulcerative colitis. Participants who responded to treatment in earlier studies can continue taking the drug for up to 2 years. The mai…

This study looks at how well and how safely the drug mirikizumab works over a long period (about 3 years) in children and teenagers with moderate-to-severe ulcerative colitis or Crohn's disease. Participants must have already been in a previous mirikizumab study and may continue …

This study looks at whether adding a special diet called the Crohn's Disease Exclusion Diet (CDED) to standard medicines can help children and teens with unstable Crohn's disease avoid flare-ups for a full year. About 120 participants aged 6-17 will be randomly assigned to either…

This study tests a subcutaneous (under-the-skin) version of vedolizumab in children aged 2-17 with moderate to severe ulcerative colitis or Crohn's disease. About 70 kids who already responded to IV vedolizumab will receive the shot for up to 34 weeks. The goal is to see how the …

This study tracks 220 adults with moderate-to-severe ulcerative colitis or Crohn's disease who are starting guselkumab, a biologic drug. Researchers will measure how many patients achieve remission (symptom control) and whether they can stop using steroids. The goal is to see how…

This study tests a new drug called tulisokibart in 1,200 people with moderate-to-severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut better than a placebo. Participants must have tried other treatments without success. The study lasts up to 52 we…

This study follows 400 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission and how the drug affects fatigue, quality of life, and daily activities. The goal is to see how well the trea…

This study tests a drug called vedolizumab for people in China with moderate to severe Crohn's disease, a condition that causes inflammation in the gut. About 408 adults will receive either the drug or a placebo to see if it reduces symptoms like belly pain and diarrhea. The goal…

This study tests whether adding a weight-loss drug (tirzepatide) to a standard Crohn's treatment (mirikizumab) helps people with both Crohn's disease and obesity or overweight. About 290 adults will receive either mirikizumab alone or mirikizumab plus tirzepatide for up to 61 wee…

This study tests an experimental drug called MORF-057 in 385 adults with moderate to severe Crohn's disease. Participants will receive one of three doses or a placebo to see if the drug can reduce gut inflammation and improve symptoms. The goal is to find a safer, more convenient…

This study tests four targeted medicines (risankizumab, trosunilimab, lutikizumab, and ABBV-8736) in about 540 adults with moderate to severe Crohn's disease. The goal is to see if these drugs can reduce gut inflammation and improve symptoms better than current treatments. Partic…

This study tests a medicine called duvakitug in people with moderate-to-severe Crohn's disease who already responded to it in an earlier study. The goal is to see if it can keep symptoms and gut inflammation under control for up to 5 years. About 671 adults will take either the d…

This study compares a newer surgical technique (Kono-S) with the standard approach for joining the ends of the intestine after removing diseased sections in people with Crohn's disease. The goal is to see if the Kono-S method better prevents the disease from returning in the join…

This study tests a new medicine called duvakitug for people with moderate to severe Crohn's disease. About 980 adults will receive either the drug or a placebo for 12 weeks to see if it reduces symptoms and heals the gut lining. The goal is to find a better treatment option for t…

This study tracks 250 adults with moderate-to-severe Crohn's disease who are switching to a second treatment (upadacitinib or risankizumab) after their first therapy stopped working well. Researchers will see if these drugs help patients achieve remission without needing steroids…

This study tests whether high-dose chemotherapy followed by a stem cell transplant can help children and adults with severe Crohn's disease. The goal is to reset the immune system and reduce inflammation. Up to 20 participants aged 10 to 60 will be enrolled. The study focuses on …

This study tests a drug called risankizumab in children aged 2 to 18 with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms like belly pain and diarrhea. Participants will receive the medicine through an IV or injection …

This study tests a special PET scan that uses a radioactive tracer to find early scarring in the small bowel of people with Crohn's disease. About 45 adults with Crohn's will get the scan to see if it can spot fibrosis before it causes blockages. The goal is to improve diagnosis …

This study compares a quick, abbreviated MRI scan to the standard longer scan in 300 children and adults with Crohn's disease. The goal is to see if the shorter scan is just as good at finding inflammation, narrowing, or other problems in the bowel. Participants will also share w…

This pilot study from Mayo Clinic tests whether virtual reality (VR) can safely reduce abdominal pain in people with Crohn's disease who are not currently experiencing active inflammation. The study will enroll 15 participants who have ongoing pain despite normal inflammation mar…

This study follows 300 adults with Crohn's disease who are starting standard treatments (vedolizumab or IL-23 blockers). Researchers will use patient questionnaires to measure how quickly symptoms like pain, fatigue, and mood improve. The goal is to better understand when patient…

This study looks at why Crohn's disease often comes back after surgery. Researchers will examine immune cells in the gut that respond to a protein called IL-23, which is known to fuel inflammation. By studying 40 patients before and after routine treatment, they hope to find bett…

This study looks at how pregnancy, childbirth, and breastfeeding affect inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers will track 945 women from the EPIMAD registry to count disease flares during and after pregnancy. The goal is to…

This study looks at how doctors around the world use a 'treat-to-target' approach for people with Crohn's disease or ulcerative colitis. Researchers will review medical records from 2,000 adults over 24 months to see if adjusting treatment based on regular check-ups leads to bett…

This study is collecting health information from up to 10,000 people with conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a smartphone app to share symptoms, health history, and wearable data. The goal is to better understand these illnesses and help…

This study is tracking 600 adults in South Korea who are already receiving vedolizumab injections for ulcerative colitis or Crohn's disease. Researchers will review medical records to see what side effects occur and how well the treatment works. No new treatments are given—this i…